bivalirudin / Generic mfg. - LARVOL DELTA

The efficacy and safety of bivalirudin and heparin in patients with acute coronary syndrome: a systematic review and meta-analysis. (PubMed, Syst Rev) - "Compared with heparin, bivalirudin has definite anticoagulant effect in patients with acute myocardial infarction after PCI, and the risk of bleeding and the incidence of retransfusion were lower in the bivalirudin group. This review helps doctors in PCI management choose bivalirudin or heparin more precisely based on patients' conditions for better treatment and fewer adverse events."

Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Bivalirudin as anticoagulation strategy for acute hemodialysis in children: Two cases with a summary of recent literature (IPNA 2025) - "Conclusions To date, experience regarding the use of bivalirudin in acute pediatric hemodialysis islacking. We presented two pediatric cases in which bivalirudin was used successfully in acutehemodialysis on a PICU."

Clinical • Hematological Disorders • Pediatrics • Thrombocytopenia

Bivalirudin functionalized hydrogel coating capable of catalytical NO-generation for enhanced anticorrosion and biocompatibility of magnesium alloy. (PubMed, Mater Today Bio) - "In the case of catalytic NO-liberation, the catalytic release of NO could further significantly improve blood compatibility, EC growth, and functional expressions of ECs. Therefore, the method in this study provides an effective strategy to fabricate the bioactive hydrogel coating that can simultaneously resist corrosion and enhance the biocompatibility of magnesium-based alloys, thereby effectively promoting research and application of magnesium alloy in intravascular stents."

Journal • Hematological Disorders • AR

Anticoagulation in patients with a history of heparin-induced thrombocytopenia who require cardiovascular surgery: is it okay to use heparin? (PubMed, Pol Arch Intern Med) - "If procedures cannot be delayed, approaches include intraoperative bivalirudin or intraoperative heparin with pre- or intraoperative plasma exchange or a potent antiplatelet agent, sometimes in combination with intravenous immunoglobulin. In subacute HIT B (immunoassay positive, functional assay negative) and remote HIT (immunoassay negative, functional assay negative), brief exposure to heparin in the intraoperative setting with close monitoring postoperatively is suggested due to the low risk of recurrent HIT."

Journal • Review • Cardiovascular • Hematological Disorders • Thrombocytopenia

SAFETY OF BIVALIRUDIN IN THE TREATMENT OF LARGE LA THROMBUS IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA WITH MITRAL BIO PROSTHESIS - Emad M. Elkholy (ACC 2025) - No abstract available

Clinical • Hematological Disorders • Thrombocytopenia • Thrombosis

BIVALIRUDIN VERSUS HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES - Yusuf K. Qadeer (ACC 2025) - No abstract available

Clinical • Acute Coronary Syndrome • Cardiovascular

AORTIC VALVE THROMBUS ASSOCIATED WITH LEFT ATRIAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION (LAVA-ECMO) WHILE ON BIVALIRUDIN - Felix Nguyen (ACC 2025) - No abstract available

Thrombosis

Use of Bivalirudin in the Management of Berlin Heart Excor as a Bridge to Heart Transplantation in Paediatric Population (ISHLT 2025) - "Abstract is embargoed at this time."

Clinical • Pediatrics • Transplantation

Burst Dosing of Bivalirudin Infusion? No Bursts of Bleeding: Experience in Children Supported with Paracorporeal Ventricular Assist Devices (ISHLT 2025) - "Abstract is embargoed at this time."

Clinical • Cardiovascular

Primary Anticoagulation with Bivalirudin vs Heparin in Patients Supported with Microaxial Flow Pump (ISHLT 2025) - "Abstract is embargoed at this time."

Clinical

Peak Procedural ACT Is Associated With All-Cause Mortality After Femoral Access PCI. (PubMed, J Soc Cardiovasc Angiogr Interv) - "Coronary artery bypass graft patients and those who received bivalirudin were excluded...There was no difference in clinical outcomes by peak ACT for patients who had radial access. Higher ACT with transfemoral access PCI was associated with increased 30-day mortality, bleeding complications, and need for blood products post-PCI."

Journal • Cardiovascular • Coronary Artery Disease • Myocardial Infarction • Pain

Anticoagulation and associated complications in veno-arterial extracorporeal membrane oxygenation in adult patients: A systematic review and meta-analysis. (PubMed, Crit Care Resusc) - "The incidence of major bleeding or thrombotic events was similar among heparin-, bivalirudin- and anticoagulation-free cohorts...Limited numbers of patients anticoagulated with alternatives to heparin were reported. Patients with additional mechanical LV unloading represent a cohort at particular risk of bleeding and thrombotic complications."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke • Novel Coronavirus Disease • Thrombosis

Interim Data Analysis-—Heparin vs. Bivalirudin and ECMO Oxygenator Performance (STS 2025) - No abstract available

Cardiovascular

Debate: Bivalirudin is the Anticoagulant of Choice in the CTICU (STS 2025) - No abstract available

Cardiovascular

A Novel Configuration of Venovenous Modified Ultrafiltration for Bivalirudin Removal After HeartMate3 Insertion. (PubMed, J Cardiothorac Vasc Anesth) - No abstract available

Journal • Cardiovascular

Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. (PubMed, BMC Cardiovasc Disord) - "In patients with UA and NSTEMI undergoing elective PCI, 80% of the recommended dose of bivalirudin without post-procedure infusion can be used for anticoagulation without increasing the risk of thrombosis and bleeding."

Journal • Observational data • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis

Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression (ASH 2024) - "15/24 (62.5%) were treated as HIT based on clinical suspicion, 4Ts scores, and OD values despite negative PEA results, most commonly with Bivalirudin followed by Warfarin or direct oral anticoagulants (DOACs). These results emphasize the importance of continuously reassessing binary tests. We propose reviewing larger data sets to assess if a separate intermediate PEA risk group might need to be defined while incorporating clinical parameters to finalize the diagnosis and help guide appropriate management."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Thrombocytopenia • SELP

Bivalirudin Monitoring By Dilute Thrombin Time Is Cost-Efficient in Pediatric ECMO Patients (ASH 2024) - "Previous studies have reported decreased need for blood product transfusions and circuit changes with bivalirudin, with favorable or equivalent total costs in MCS patients. This work demonstrates that dTT monitoring of bivalirudin in pediatric patients during the first 5 days of ECMO is cost-efficient and potentially reduces total laboratory test/blood volume sampling."

Clinical • Cardiovascular • Hematological Disorders • Pediatrics • Thrombosis

Comparison of short-to medium-term ischemia and bleeding risks between unfractionated heparin and bivalirudin in patients with acute coronary syndrome after PCI (PubMed, Zhonghua Yi Xue Za Zhi) - "The cumulative incidence of bleeding events was 9.9% in unfractionated heparin group and 4.5% in bivalirudin group (P=0.005); The cumulative incidence of ischemic events was 11.2% in unfractionated heparin group and 9.5% in bivalirudin group (P=0.459). The incidence of short-term hemorrhage events in ACS patients treated with bivalirudin anticoagulation after emergency PCI is lower than that of unfractonated heparin, which can reduce the risk of short-term hemorrhage."

Clinical • Journal • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders

Troubleshooting heparin resistance. (PubMed, Hematology Am Soc Hematol Educ Program) - "Multiple causes of apparent heparin resistance include hypercoagulability, antithrombin deficiency, andexanet alfa used for direct oral anticoagulant reversal, thrombocytosis, and antiphospholipid antibody syndromes. Treatment options for managing patients with heparin resistance include weight-based dosing and administration of additional UFH, antithrombin supplementation, or the use of an alternative anticoagulant such as the direct thrombin inhibitors bivalirudin or argatroban."

Journal • Review • Critical care • Hematological Disorders • Infectious Disease • Inflammation • Novel Coronavirus Disease • Thrombocytosis

Management of Refractory Heparin-Induced Thrombocytopenia with Ivig, Plasma Exchange, and Rituximab: A Case Report (ASH 2024) - "Argatroban was started, and thrombectomy of her lower extremity was performed...IVIg was initiated for 3 days, and AC was transitioned to bivalirudin...Additional research into the pathophysiology and management of this entity is needed.Conclusion : There are no current guidelines for treating severe refractory HIT. Further investigation is necessary to assess the role of autoimmunity and immunosuppression in managing this life-threatening condition."

Case report • Clinical • Cardiovascular • Hematological Disorders • Pain • Thrombocytopenia

Impact of Discordant aPTT and Bivalirudin Levels on Bleeding and Clotting Outcomes in Critically Ill Pediatric Patients ReceivingVAECMO A SingleCenter Retrospective Cohort Study (ASHP 2024) - No abstract available

Discordant • Retrospective data • Pediatrics

Comparison of Bivalirudin Versus Heparin in Patients Receiving VenoVenous Extracorporeal Membrane Oxygenation VVECMO (ASHP 2024) - No abstract available

Clinical

HIT Me with Your Best Clot A Retrospective Comparison Review of Bivalirudin and Argatroban When Used for Incidences of Suspected or Confirmed HeparinInduced Thrombocytopenia (ASHP 2024) - No abstract available

Retrospective data • Review • Hematological Disorders • Thrombocytopenia

Evaluation of Bivalirudin Titration Protocol in Patients With Temporary Heart Pumps (ASHP 2024) - No abstract available

Clinical